Prot#XL184-306: A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer

  • Kuzel, Timothy Michael (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date8/6/12 → 8/6/15

Funding

  • Exelixis Inc. (XL184-306)